欧盟 - 丹麦文 - EMA (European Medicines Agency)

bristol-myers squibb pharma eeig - ipilimumab - melanoma; carcinoma, renal cell; carcinoma, non-small-cell lung; mesothelioma, malignant; colorectal neoplasms - antineoplastiske midler - melanomayervoy as monotherapy or combination with nivolumab is indicated for the treatment of advanced (unresectable or metastatic) melanoma in adults and adolescents 12 years of age and older (see section 4.  yervoy in combination with nivolumab is indicated for the treatment of advanced (unresectable or metastatic) melanoma in adults. relative to nivolumab monotherapy, an increase in progression-free survival (pfs) and overall survival (os) for the combination of nivolumab with ipilimumab is established only in patients with low tumour pd-l1 expression (see sections 4. 4 og 5. renal cell carcinoma (rcc)yervoy in combination with nivolumab is indicated for the first-line treatment of adult patients with intermediate/poor-risk advanced renal cell carcinoma (see section 5. non-small cell lung cancer (nsclc)yervoy in combination with nivolumab and 2 cycles of platinum-based chemotherapy is indicated for the first-line treatment of metastatic non-small cell lung cancer in adults whose tumours have no sensitising egfr mutation or alk translocation. malignant pleural mesothelioma (mpm)yervoy in combination with nivolumab is indicated for the first-line treatment of adult patients with unresectable malignant pleural mesothelioma. mismatch repair deficient (dmmr) or microsatellite instability-high (msi-h) colorectal cancer (crc)yervoy in combination with nivolumab is indicated for the treatment of adult patients with mismatch repair deficient or microsatellite instability-high metastatic colorectal cancer after prior fluoropyrimidine based combination chemotherapy (see section 5. oesophageal squamous cell carcinoma (oscc)yervoy in combination with nivolumab is indicated for the first-line treatment of adult patients with unresectable advanced, recurrent or metastatic oesophageal squamous cell carcinoma with tumour cell pd-l1 expression ≥ 1%.

丹麦 - 丹麦文 - Lægemiddelstyrelsen (Danish Medicines Agency)

janssen-cilag a/s - ethinylestradiol, norgestimat - filmovertrukne tabletter - 250 + 35 mikrogram

丹麦 - 丹麦文 - Lægemiddelstyrelsen (Danish Medicines Agency)

orifarm a/s - ethinylestradiol, norgestimat - tabletter - 250+35 mikrogram

丹麦 - 丹麦文 - Lægemiddelstyrelsen (Danish Medicines Agency)

accord healthcare b.v. - clozapin - tabletter - 100 mg

丹麦 - 丹麦文 - Lægemiddelstyrelsen (Danish Medicines Agency)

sandoz a/s - phenoxymethylpenicillinkalium - filmovertrukne tabletter - 500.000 ie

丹麦 - 丹麦文 - Lægemiddelstyrelsen (Danish Medicines Agency)

baxter holding b.v. - propofol - injektions-/infusionsvæske, emulsion - 10 mg/ml

欧盟 - 丹麦文 - EMA (European Medicines Agency)

ipsen pharma - somatropin - turner syndrome; dwarfism, pituitary - hypofysiske og hypotalamiske hormoner og analoger - langsigtet behandling af børn med vækstfejl på grund af utilstrækkelig endogen væksthormonsekretion. langsigtet behandling af vækstforstyrrelser i forbindelse med turner syndrom. behandling af præpubertale børn med vækstforstyrrelser, der er forbundet med kronisk nyreinsufficiens op til tidspunktet for renal transplantation. udskiftning af endogene væksthormon hos voksne med væksthormon mangel af enten barndom eller voksen-debut ætiologi. væksthormon mangel, skal være bekræftet passende forud for behandlingen.

丹麦 - 丹麦文 - Lægemiddelstyrelsen (Danish Medicines Agency)

sandoz gmbh - cefotaximnatrium - pulver til injektions-/infusionsvæske, opløsning - 1 g

丹麦 - 丹麦文 - Lægemiddelstyrelsen (Danish Medicines Agency)

sandoz gmbh - cefotaximnatrium - pulver til injektions-/infusionsvæske, opløsning - 2 g

丹麦 - 丹麦文 - Lægemiddelstyrelsen (Danish Medicines Agency)

sandoz gmbh - cefotaximnatrium - pulver til injektionsvæske, opløsning - 0,5 g